About 500 patients will be enrolled in the trial, which will compare daratumumab in combination with lenalidomide and dexamethasone to lenalidomide and dexamethasone alone. The company intends to
Under the deal, ProBioGen is granting Merus the non-exclusive right to use the GlymaxX technology to improve the ADCC (Antibody-Dependent Cell-Mediated Cytotoxicity) activity of one of its lead
Regulus Therapeutics’ Phase I study is being conducted in the Netherlands. Primary objective of the Phase I study is to assess the safety and tolerability of RG-101, while
The company said that proceeds from the financing will be used to advance development of its lead product candidate ZS-9, for the treatment of hyperkalemia, through its new
Jetrea is a selective proteolytic enzyme that cleaves fibronectin, laminin and collagen, three major components of the vitreoretinal interface that play a major role in VMA. The Ocriplasmin
The deal will see the companies provide a wider range of drug discovery and translational medicine services, including expanded profiling and molecule testing, especially in the context of
CFFT is the non-profit drug discovery and development affiliate of the Cystic Fibrosis Foundation. The extension will focus on moving the company’s lead compounds toward a development candidate
The company said that the licence agreement is with the same partner that will be supplying the women’s health product that is being prepared for launch in the
The company has announced this voluntary recall to the user level following the discovery of four leaking premix bags during an investigation conducted in response to a product
OMS721 is the company’s lead human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2), the key regulator of the lectin pathway of the immune system. In the trial,
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.